TY - JOUR
T1 - Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
AU - the CoMo Consortium
AU - Águas, Ricardo
AU - Mahdi, Adam
AU - Shretta, Rima
AU - Horby, Peter
AU - Landray, Martin
AU - White, Lisa
AU - Arifi, Fatima
AU - Zhumalieva, Chynar
AU - Lubis, Inke N.D.
AU - Monteiro, Antoninho Benjamin
AU - Moldokmatova, Ainura
AU - Chen, Siyu
AU - Estebesova, Aida
AU - Hussain, Mofakhar
AU - Lata, Dipti
AU - Bakare, Emmanuel A.
AU - Getachew, Biniam
AU - Sahak, Mohammad Nadir
AU - Chanthavilay, Phetsavanh
AU - Nji, Akindeh M.
AU - Aung, Yu Nandar
AU - Hupert, Nathaniel
AU - Tun, Sai Thein Than
AU - Pan-Ngum, Wirichada
AU - Sarin, K. C.
AU - Harsono, Handoyo
AU - Eybpoosh, Sana
AU - Coutinho, Renato Mendes
AU - Omoleke, Semeeh A.
AU - Nwosu, Amen Patrick
AU - Luangasanatip, Nantasit
AU - Kutmanova, Ainura
AU - Dooronbekova, Aizhan
AU - Ximenes, Antonio
AU - Monteiro, Merita
AU - Celhay, Olivier
AU - Adib, Keyrellous
AU - Salim, Amel H.
AU - Yunanda, Yuki
AU - Fariba, Mahnaz Hossain
AU - Azzeri, Amirah
AU - Hancock, Penny
AU - Bekrizadeh, Hakim
AU - Saeedzai, Sayed Ataullah
AU - Alona, Ivana
AU - Mzumara, Grace Wezi
AU - Martins, Joao
AU - Herrera-Diestra, Jose L.
AU - Sharifi, Hamid
AU - Abdyldaev, Talant
AU - Jamshidi, Babak
AU - Hairi, Noran Naqiah
AU - Nasir, Naima
AU - Zaman, Rashid U.
AU - Obiesie, Sopuruchukwu
AU - Kraenkel, Roberto A.
AU - Letchford, Nicholas
AU - Alves, Lucsendar Raimunda Fernandes
AU - Adele, Sandra
AU - Suárez-Idueta, Lorena
AU - Advani, Nicole
AU - Marzouk, Manar
AU - Mabombo, Viviana
AU - Mukambetov, Aibek
AU - Aderoba, Adeniyi Kolade
AU - Tbalasubramaniam, Bpriya Lakshmy
AU - de Colombi, Nicole Feune
AU - Niha, Maria Angela Varela
AU - Obando, Francisco
AU - Wattanasri, Parinda
AU - Saralamba, Sompob
AU - Shabaruddin, Fatiha
AU - Shimul, Shafiun Nahin
AU - Dahlui, Maznah
AU - Naidoo, Reshania
AU - Franco, Caroline
AU - Klein, Michael G.
AU - Kubatova, Aisuluu
AU - Jabin, Nusrat
AU - Kyaw, Shwe Sin
AU - Freitas, Luzia Tomas
AU - Pokharel, Sunil
AU - Ariana, Proochista
AU - Mercado, Chris Erwin G.
AU - Ibragimov, Shamil
AU - Medina, John Robert C.
AU - Namedre, Mesulame
PY - 2021/2/10
Y1 - 2021/2/10
N2 - Dexamethasone can reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment were to be rolled out in the UK and globally, as well as the cost-effectiveness of implementing this intervention. Assuming SARS-CoV-2 exposure levels of 5% to 15%, we estimate that, for the UK, approximately 12,000 (4,250 - 27,000) lives could be saved between July and December 2020. Assuming that dexamethasone has a similar effect size in settings where access to oxygen therapies is limited, this would translate into approximately 650,000 (240,000 - 1,400,000) lives saved globally over the same time period. If dexamethasone acts differently in these settings, the impact could be less than half of this value. To estimate the full potential of dexamethasone in the global fight against COVID-19, it is essential to perform clinical research in settings with limited access to oxygen and/or ventilators, for example in low- and middle-income countries.
AB - Dexamethasone can reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment were to be rolled out in the UK and globally, as well as the cost-effectiveness of implementing this intervention. Assuming SARS-CoV-2 exposure levels of 5% to 15%, we estimate that, for the UK, approximately 12,000 (4,250 - 27,000) lives could be saved between July and December 2020. Assuming that dexamethasone has a similar effect size in settings where access to oxygen therapies is limited, this would translate into approximately 650,000 (240,000 - 1,400,000) lives saved globally over the same time period. If dexamethasone acts differently in these settings, the impact could be less than half of this value. To estimate the full potential of dexamethasone in the global fight against COVID-19, it is essential to perform clinical research in settings with limited access to oxygen and/or ventilators, for example in low- and middle-income countries.
UR - http://www.scopus.com/inward/record.url?scp=85101016964&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-21134-2
DO - 10.1038/s41467-021-21134-2
M3 - Article
C2 - 33568665
AN - SCOPUS:85101016964
VL - 12
SP - 1
EP - 8
JO - Nature Communications
JF - Nature Communications
SN - 2041-1723
IS - 1
M1 - 915
ER -